Z
Zhuxuan Jiang
Researcher at Fudan University
Publications - 7
Citations - 390
Zhuxuan Jiang is an academic researcher from Fudan University. The author has contributed to research in topics: Drug delivery & Targeted drug delivery. The author has an hindex of 4, co-authored 5 publications receiving 208 citations.
Papers
More filters
Journal ArticleDOI
Brain-targeted drug delivery by manipulating protein corona functions.
Zui Zhang,Juan Guan,Zhuxuan Jiang,Yang Yang,Jican Liu,Wei Hua,Ying Mao,Cheng Li,Weiyue Lu,Jun Qian,Changyou Zhan +10 more
TL;DR: In this article, bio-inspired liposomes (SP-sLip) were developed by modifying liposomal surface with a short nontoxic peptide derived from Aβ1-42 that specifically interacts with the lipid-binding domain of exchangeable apolipoproteins.
Journal ArticleDOI
Peptide ligand-mediated targeted drug delivery of nanomedicines
TL;DR: Peptide ligands are advantageous over other classes of targeting ligands due to their accessibility of high-throughput screening, ease of synthesis, high specificity and affinity, etc.
Journal ArticleDOI
Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption.
Juan Guan,Qing Shen,Zui Zhang,Zhuxuan Jiang,Yang Yang,Meiqing Lou,Jun Qian,Weiyue Lu,Changyou Zhan +8 more
TL;DR: Liposomes are modified with a peptidomimetic that preserves bioactivity of the nanocarrier in blood circulation and attenuates IgM absorption, thereby improving the immunocompatibility of brain-targeted liposomes.
Journal ArticleDOI
Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility.
Juan Guan,Zhuxuan Jiang,Mengke Wang,Ying Liu,Jican Liu,Yang Yang,Tianhao Ding,Weiyue Lu,Chunli Gao,Jun Qian,Changyou Zhan +10 more
TL;DR: The results suggest that short peptide ligand-mediated brain-targeted drug delivery systems possessing enhanced immunocompatibility are promising to facilitate efficient brain transport with improved biosafety.
Journal ArticleDOI
Self-Adjuvant Effect by Manipulating the Bionano Interface of Liposome-Based Nanovaccines.
TL;DR: In this article, a self-adjuvant was validated by regulating antigen-presenting cells recognition of liposome-based nanovaccines, showing significant splenic B cells targeting.